A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Key Inclusion Criteria:

• Must sign the informed consent form (ICF) and be capable of giving written informedconsent, which includes compliance with the requirements and restrictions listed inthe ICF

• Confirmed diagnosis of a R/R B-cell malignancy

• Protocol-defined measurable disease

• Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

• Adequate organ function

• Female participants of childbearing potential must be willing to use a highlyeffective method of birth control and refrain from egg donation for the duration ofthe study and for 30 days after the last dose of BGB-16673 or zanubrutinib, 60 daysafter the last dose of glofitamab, or 90 days after the last dose of sonrotoclax ormosunetuzumab. A negative urine or serum pregnancy test result must be provided 10-14 days before the first dose of study treatment

• Nonsterile male participants must be willing to use a highly effective method ofbirth control and refrain from sperm donation for the duration of the study and for 30 days after the last dose of BGB-16673 or zanubrutinib, 60 days after the lastdose of glofitamab, or 90 days after the last dose of sonrotoclax or mosunetuzumab

• Substudies 1, 3, and 4 Inclusion Criterion:

• Adequate renal function as indicated by estimated glomerular filtration rate (eGFR) of ≥ 50 mL/min

• Substudy 2 Inclusion Criteria:

• Bruton tyrosine kinase (BTK) inhibitor-naive, or previously received treatmentwith a covalent BTK inhibitor and discontinued for reasons other than clinicalprogression

• Adequate renal function as indicated by eGFR of ≥ 30 mL/min

Key Exclusion Criteria:

• Treatment-naive B-cell malignancies

• Unable to comply with the requirements of the protocol

• Active leptomeningeal disease or uncontrolled, untreated brain metastasis

• Any malignancy ≤ 2 years before first dose of study treatment except for thespecific cancer under investigation in this study or any locally recurring cancerthat has been treated curatively

• Autologous stem cell transplant ≤ 3 months prior to screening or chimeric antigenT-cell therapy ≤ 3 months prior to screening

• Substudies 1 and 2: Prior allogeneic stem cell transplant with activegraft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatmentof GVHD, or who have taken calcineurin inhibitors within 4 weeks prior to consent

• Participants who have a history of severe allergic reactions or hypersensitivity tothe active ingredient and excipients of BGB-16673, sonrotoclax, zanubrutinib,mosunetuzumab, or glofitamab

• Substudy 1 Exclusion Criterion:

• Prior treatment with a B-cell lymphoma-2 (Bcl-2) inhibitor (with exception forparticipants who relapsed ≥ 24 months after completion of a full course of aprior Bcl-2 inhibitor containing regimen)

• Substudy 2 Exclusion Criterion:

• Participants who discontinued prior zanubrutinib treatment due to intolerance

• Substudies 3 and 4 Exclusion Criteria:

• Prior exposure to a CD20 x CD3 T-cell engager antibody treatment

• All participants with a prior allogeneic stem cell transplant

Note: Other protocol defined Inclusion/Exclusion criteria may apply.